Sci Rep:CXCR4调节脊髓神经元中的CaMKII / CREB途径诱发癌症骨痛的机制

2017-06-22 Yara MedSci原创

研究人员发现CXCR4有助于激活癌症诱导的骨痛中的神经元CaMKII / CREB途径。

由原发性骨肿瘤或肿瘤转移到骨骼的癌症诱导的骨痛(CIBP)仍然是癌症疼痛最常见和令人痛心的类型之一。最近的流行病学研究已经证明,大约一半以上的转移性或晚期骨癌患者每天都会经历中度至重度的癌症疼痛,严重破坏了他们的生活质量。一般由病理突破疼痛和持续疼痛组成的癌症疼痛症状通过使用常规镇痛药和治疗方法仍然有很多不足之处,这部分是由于我们目前对这种疼痛的具体机制还了解不足。
趋化因子受体CXCR4通过激活脊髓神经元和神经胶质细胞在癌症诱导的骨痛中起重要作用。然而,CXCR4信号的特异性神经元及其机制尚不清楚。研究人员发现CXCR4有助于激活癌症诱导的骨痛中的神经元CaMKII / CREB途径。通过使用肿瘤细胞植入(TCI)模型,观察到CXCR4,p-CaMKII和p-CREB在脊髓神经元中持续上调。CXCR4还与p-CaMKII和p-CREB共表达,并在TCI后介导p-CaMKII和p-CREB表达。 CXCR4 siRNA或CaMKII抑制剂AIP2的鞘内输送消除了TCI诱导的疼痛超敏反应和TCI诱导的p-CaMKII和p-CREB表达的增加。通过在初始大鼠鞘内注射CXCR4,SDF-1的主要配体,可以促进p-CaMKII和p-CREB表达,这种促进作用可以通过给予CXCR4抑制剂Plerixafor或PLC抑制剂U73122而防止。 Plerixafor,U73122或AIP2也缓解了SDF-1引起的疼痛行为。鞘内注射CXCR4 siRNA显着抑制TCI诱导的NMDAR1 mRNA和蛋白上调,这是CREB的已知基因靶标。总之,这些结果表明脊髓神经元中的CaMKII / CREB途径介导了癌症大鼠中CXCR4促进的疼痛超敏反应。

原文出处:

本文系梅斯医生(Medsci)原创整理编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1675307, encodeId=72a916e5307dc, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Tue May 29 07:34:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954109, encodeId=c9f0195410972, content=<a href='/topic/show?id=e369400476' target=_blank style='color:#2F92EE;'>#CaMKII#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4004, encryptionId=e369400476, topicName=CaMKII)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Sep 05 20:34:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412448, encodeId=40b2141244811, content=<a href='/topic/show?id=c5d95546ff' target=_blank style='color:#2F92EE;'>#CXCR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5546, encryptionId=c5d95546ff, topicName=CXCR4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c832868137, createdName=chenwq09, createdTime=Sat Jun 24 05:34:00 CST 2017, time=2017-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581460, encodeId=cda9158146005, content=<a href='/topic/show?id=2bc1519579' target=_blank style='color:#2F92EE;'>#CRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5195, encryptionId=2bc1519579, topicName=CRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ca216802819, createdName=HinsMax, createdTime=Sat Jun 24 05:34:00 CST 2017, time=2017-06-24, status=1, ipAttribution=)]
    2018-05-29 whmdzju
  2. [GetPortalCommentsPageByObjectIdResponse(id=1675307, encodeId=72a916e5307dc, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Tue May 29 07:34:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954109, encodeId=c9f0195410972, content=<a href='/topic/show?id=e369400476' target=_blank style='color:#2F92EE;'>#CaMKII#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4004, encryptionId=e369400476, topicName=CaMKII)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Sep 05 20:34:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412448, encodeId=40b2141244811, content=<a href='/topic/show?id=c5d95546ff' target=_blank style='color:#2F92EE;'>#CXCR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5546, encryptionId=c5d95546ff, topicName=CXCR4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c832868137, createdName=chenwq09, createdTime=Sat Jun 24 05:34:00 CST 2017, time=2017-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581460, encodeId=cda9158146005, content=<a href='/topic/show?id=2bc1519579' target=_blank style='color:#2F92EE;'>#CRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5195, encryptionId=2bc1519579, topicName=CRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ca216802819, createdName=HinsMax, createdTime=Sat Jun 24 05:34:00 CST 2017, time=2017-06-24, status=1, ipAttribution=)]
    2017-09-05 仁医06
  3. [GetPortalCommentsPageByObjectIdResponse(id=1675307, encodeId=72a916e5307dc, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Tue May 29 07:34:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954109, encodeId=c9f0195410972, content=<a href='/topic/show?id=e369400476' target=_blank style='color:#2F92EE;'>#CaMKII#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4004, encryptionId=e369400476, topicName=CaMKII)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Sep 05 20:34:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412448, encodeId=40b2141244811, content=<a href='/topic/show?id=c5d95546ff' target=_blank style='color:#2F92EE;'>#CXCR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5546, encryptionId=c5d95546ff, topicName=CXCR4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c832868137, createdName=chenwq09, createdTime=Sat Jun 24 05:34:00 CST 2017, time=2017-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581460, encodeId=cda9158146005, content=<a href='/topic/show?id=2bc1519579' target=_blank style='color:#2F92EE;'>#CRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5195, encryptionId=2bc1519579, topicName=CRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ca216802819, createdName=HinsMax, createdTime=Sat Jun 24 05:34:00 CST 2017, time=2017-06-24, status=1, ipAttribution=)]
    2017-06-24 chenwq09
  4. [GetPortalCommentsPageByObjectIdResponse(id=1675307, encodeId=72a916e5307dc, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Tue May 29 07:34:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954109, encodeId=c9f0195410972, content=<a href='/topic/show?id=e369400476' target=_blank style='color:#2F92EE;'>#CaMKII#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4004, encryptionId=e369400476, topicName=CaMKII)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Sep 05 20:34:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412448, encodeId=40b2141244811, content=<a href='/topic/show?id=c5d95546ff' target=_blank style='color:#2F92EE;'>#CXCR4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5546, encryptionId=c5d95546ff, topicName=CXCR4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c832868137, createdName=chenwq09, createdTime=Sat Jun 24 05:34:00 CST 2017, time=2017-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581460, encodeId=cda9158146005, content=<a href='/topic/show?id=2bc1519579' target=_blank style='color:#2F92EE;'>#CRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5195, encryptionId=2bc1519579, topicName=CRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ca216802819, createdName=HinsMax, createdTime=Sat Jun 24 05:34:00 CST 2017, time=2017-06-24, status=1, ipAttribution=)]
    2017-06-24 HinsMax